119 related articles for article (PubMed ID: 24170211)
1. PIASγ expression in relation to clinicopathological, tumour factors and survival in indigenous black breast cancer women.
Agboola A; Musa A; Banjo A; Ayoade B; Deji-Agboola M; Nolan C; Rakha E; Ellis I; Green A
J Clin Pathol; 2014 Apr; 67(4):301-6. PubMed ID: 24170211
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathological and molecular significance of Sumolyation marker (ubiquitin conjugating enzyme 9 (UBC9)) expression in breast cancer of black women.
Agboola AO; Musa AA; Ayoade BA; Banjo AA; Anunobi CC; Deji-Agboola AM; Rakha EA; Nolan C; Ellis IO; Green AR
Pathol Res Pract; 2014 Jan; 210(1):10-7. PubMed ID: 24176171
[TBL] [Abstract][Full Text] [Related]
3. Molecular characteristics and prognostic features of breast cancer in Nigerian compared with UK women.
Agboola AJ; Musa AA; Wanangwa N; Abdel-Fatah T; Nolan CC; Ayoade BA; Oyebadejo TY; Banjo AA; Deji-Agboola AM; Rakha EA; Green AR; Ellis IO
Breast Cancer Res Treat; 2012 Sep; 135(2):555-69. PubMed ID: 22842985
[TBL] [Abstract][Full Text] [Related]
4. Molecular profiling of breast cancer in Nigerian women identifies an altered p53 pathway as a major mechanism underlying its poor prognosis compared with British counterpart.
Agboola AO; Banjo AA; Anunobi CC; Ayoade BA; Deji-Agboola AM; Musa AA; Abdel-Fatah T; Nolan CC; Rakha EA; Ellis IO; Green AR
Malays J Pathol; 2014 Apr; 36(1):3-17. PubMed ID: 24763230
[TBL] [Abstract][Full Text] [Related]
5. Tumour cell membrane laminin expression is associated with basal-like phenotype and poor survival in Nigerian breast cancer.
Agboola AO; Ebili HO; Iyawe VO; Banjo AA; Salami BS; Rakha EA; Nolan C; Ellis IO; Green AR
Malays J Pathol; 2016 Aug; 38(2):83-92. PubMed ID: 27568664
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathological and molecular characteristics of Ku 70/80 expression in Nigerian breast cancer and its potential therapeutic implications.
Agboola AO; Ebili HO; Iyawe VO; Banjo AA; Salami BA; Rakha EA; Nolan CC; Ellis IO; Green AR
Pathol Res Pract; 2017 Jan; 213(1):27-33. PubMed ID: 27914769
[TBL] [Abstract][Full Text] [Related]
7. Biological and clinical significance of PARP1 protein expression in breast cancer.
Green AR; Caracappa D; Benhasouna AA; Alshareeda A; Nolan CC; Macmillan RD; Madhusudan S; Ellis IO; Rakha EA
Breast Cancer Res Treat; 2015 Jan; 149(2):353-62. PubMed ID: 25528020
[TBL] [Abstract][Full Text] [Related]
8. Cell Proliferation (KI-67) Expression Is Associated with Poorer Prognosis in Nigerian Compared to British Breast Cancer Women.
Agboola AO; Banjo AA; Anunobi CC; Salami B; Agboola MD; Musa AA; Nolan CC; Rakha EA; Ellis IO; Green AR
ISRN Oncol; 2013; 2013():675051. PubMed ID: 23691362
[TBL] [Abstract][Full Text] [Related]
9. PIASγ controls stability and facilitates SUMO-2 conjugation to CoREST family of transcriptional co-repressors.
Sáez JE; Arredondo C; Rivera C; Andrés ME
Biochem J; 2018 Apr; 475(8):1441-1454. PubMed ID: 29555846
[TBL] [Abstract][Full Text] [Related]
10. Histological Features and Tissue Microarray Taxonomy of Nigerian Breast Cancer Reveal Predominance of the High-Grade Triple-Negative Phenotype.
Titloye NA; Foster A; Omoniyi-Esan GO; Komolafe AO; Daramola AO; Adeoye OA; Adisa AO; Manoharan A; Pathak D; D'Cruz MN; Alizadeh Y; Lewis PD; Shaaban AM
Pathobiology; 2016; 83(1):24-32. PubMed ID: 26730581
[TBL] [Abstract][Full Text] [Related]
11. Prognostic impact of the cancer stem cell related markers ALDH1 and EZH2 in triple negative and basal-like breast cancers.
De Brot M; Rocha RM; Soares FA; Gobbi H
Pathology; 2012 Jun; 44(4):303-12. PubMed ID: 22544210
[TBL] [Abstract][Full Text] [Related]
12. Increased ID4 expression, accompanied by mutant p53 accumulation and loss of BRCA1/2 proteins in triple-negative breast cancer, adversely affects survival.
Thike AA; Tan PH; Ikeda M; Iqbal J
Histopathology; 2016 Apr; 68(5):702-12. PubMed ID: 26259780
[TBL] [Abstract][Full Text] [Related]
13. KPNA2 is a nuclear export protein that contributes to aberrant localisation of key proteins and poor prognosis of breast cancer.
Alshareeda AT; Negm OH; Green AR; Nolan CC; Tighe P; Albarakati N; Sultana R; Madhusudan S; Ellis IO; Rakha EA
Br J Cancer; 2015 Jun; 112(12):1929-37. PubMed ID: 25989275
[TBL] [Abstract][Full Text] [Related]
14. Characteristics of basal cytokeratin expression in breast cancer.
Alshareeda AT; Soria D; Garibaldi JM; Rakha E; Nolan C; Ellis IO; Green AR
Breast Cancer Res Treat; 2013 May; 139(1):23-37. PubMed ID: 23588953
[TBL] [Abstract][Full Text] [Related]
15. Complex regulation of orphan nuclear receptor Nur77 (Nr4a1) transcriptional activity by SUMO2 and PIASγ.
Dodat F; Cotnoir-White D; Dianati E; Vallet A; Mader S; Lévesque D
Biochim Biophys Acta Mol Cell Res; 2021 Feb; 1868(2):118908. PubMed ID: 33189785
[TBL] [Abstract][Full Text] [Related]
16. Expression of epidermal growth factor receptor in relation to BRCA1 status, basal-like markers and prognosis in breast cancer.
Arnes JB; Bégin LR; Stefansson I; Brunet JS; Nielsen TO; Foulkes WD; Akslen LA
J Clin Pathol; 2009 Feb; 62(2):139-46. PubMed ID: 18682421
[TBL] [Abstract][Full Text] [Related]
17. Comparisons of p53, KI67 and BRCA1 expressions in patients with different molecular subtypes of breast cancer and their relationships with pathology and prognosis.
Li Y; Zhang X; Qiu J; Pang T; Huang L; Zeng Q
J BUON; 2019; 24(6):2361-2368. PubMed ID: 31983107
[TBL] [Abstract][Full Text] [Related]
18. BRCA1 promoter hypermethylation, 53BP1 protein expression and PARP-1 activity as biomarkers of DNA repair deficit in breast cancer.
Jacot W; Thezenas S; Senal R; Viglianti C; Laberenne AC; Lopez-Crapez E; Bibeau F; Bleuse JP; Romieu G; Lamy PJ
BMC Cancer; 2013 Nov; 13():523. PubMed ID: 24191908
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological significance of KU70/KU80, a key DNA damage repair protein in breast cancer.
Alshareeda AT; Negm OH; Albarakati N; Green AR; Nolan C; Sultana R; Madhusudan S; Benhasouna A; Tighe P; Ellis IO; Rakha EA
Breast Cancer Res Treat; 2013 Jun; 139(2):301-10. PubMed ID: 23624778
[TBL] [Abstract][Full Text] [Related]
20. Alpha- and beta-adrenergic receptor (AR) protein expression is associated with poor clinical outcome in breast cancer: an immunohistochemical study.
Powe DG; Voss MJ; Habashy HO; Zänker KS; Green AR; Ellis IO; Entschladen F
Breast Cancer Res Treat; 2011 Nov; 130(2):457-63. PubMed ID: 21298476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
